Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Baseline characteristics of RA patients included in the IL-33 ancillary study from the SMART trial and a comparison between the patients in the SMART cohort included in the IL-33 study (cohort 1, n = 111) and the rest of the cohort not assessed for serum IL-33 level (n = 113)

From: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis

  Cohort 1 Patients in the SMART cohort without IL-33 dosage Whole SMART cohort Inter-group comparison
(n = 111) (n = 113) (n = 224)
Age (years) 56 ± 11 56 ± 11 56 ± 11 0.99
Female 95 (86%) 92 (81%) 187 (84%) 0.401
Disease duration (years) 11 (1–42) 10 (0.8–45) 11 (0.8–45) 0.094
DAS28-CRP 5.8 ± 0.8 5.8 ± 0.9 5.8 ± 0.9 0.791
HAQ-DI 1.8 ± 0.6 1.8 ± 0.6 1.8 ± 0.6 0.753
Prednisone treatment 76 (68%) 88 (78%) 165 (74%) 0.11
Prednisone dosage (mg/day) 8 (2–20) 10 (2–15)* 10 (2–20)* 0.243
MTX (mg/week) 14 ± 4 14 ± 4 14 ± 4 0.351
Previous biologic: None/mAb/Eta 8 (7%)/66 (60%)/37(33%) 7 (6%)/70(62%)/36(32%) 15 (7%)/136 (61%)/73(33%) 0.914
Positive RF 76 (69%) 68 (61%) 144 (65%) 0.226
Positive anti-CCP 92 (83%) 78 (70%) 170 (76%) 0.02
Serum IgG level (g/L) 11.8 (4.6–19.2) 12 (5.4–23.3) 12 (4.6–23.3) 0.564
CRP level (mg/L) 12 (0.4–139) 11 (0.3–102) 11 (0.3–139) 0.938
Radiographic erosions 100 (90%) 98 (87%) 198 (88%) 0.432
MTX duration (years) 3.6 (0.1–20.8) 3.2 (0.3–20.5) 3.5 (0.1–20.8) 0.856
Time since last anti-TNF (months) 2.7 (0.6–64.4) 2.8 (1.2–73.6) 2.7 (0.6–73.6) 0.458
  1. Values are shown as means and standard deviations (mean ± SD) or medians (range) for continuous data, and n (%) for qualitative data
  2. *Some patients had a deviation protocol concerning the authorized prednisone dosage
  3. anti-CCP anti-cyclic citrullinated peptide antibody, CRP C-reactive protein, DAS28 Disease Activity Score in 28 joints, Eta etanercept, HAQ-DI Health Assessment Questionnaire—Disease Index, IL interleukin, mAb monoclonal antibody, MTX methotrexate, RF rheumatoid factor, TNF tumor necrosis factor